Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gad A Getz, Ph.D.

Co-Author

This page shows the publications co-authored by Gad Getz and Michael Lawrence.
Connection Strength

4.594
  1. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014 Jan 23; 505(7484):495-501.
    View in: PubMed
    Score: 0.584
  2. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013 Jul 11; 499(7457):214-218.
    View in: PubMed
    Score: 0.562
  3. Passenger Hotspot Mutations in Cancer. Cancer Cell. 2019 09 16; 36(3):288-301.e14.
    View in: PubMed
    Score: 0.217
  4. Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. Nat Commun. 2018 05 01; 9(1):1746.
    View in: PubMed
    Score: 0.197
  5. Analysis of somatic microsatellite indels identifies driver events in human tumors. Nat Biotechnol. 2017 Oct; 35(10):951-959.
    View in: PubMed
    Score: 0.188
  6. A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet. 2017 Oct; 49(10):1476-1486.
    View in: PubMed
    Score: 0.188
  7. Recurrent and functional regulatory mutations in breast cancer. Nature. 2017 07 06; 547(7661):55-60.
    View in: PubMed
    Score: 0.186
  8. Mutational Strand Asymmetries in Cancer Genomes Reveal Mechanisms of DNA Damage and Repair. Cell. 2016 Jan 28; 164(3):538-49.
    View in: PubMed
    Score: 0.168
  9. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proc Natl Acad Sci U S A. 2015 Oct 06; 112(40):E5486-95.
    View in: PubMed
    Score: 0.164
  10. Oncotator: cancer variant annotation tool. Hum Mutat. 2015 Apr; 36(4):E2423-9.
    View in: PubMed
    Score: 0.159
  11. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013 Mar; 31(3):213-9.
    View in: PubMed
    Score: 0.137
  12. Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. Mod Pathol. 2021 02; 34(2):264-279.
    View in: PubMed
    Score: 0.058
  13. Identification of Somatically Acquired BRCA1/2 Mutations by cfDNA Analysis in Patients with Metastatic Breast Cancer. Clin Cancer Res. 2020 09 15; 26(18):4852-4862.
    View in: PubMed
    Score: 0.057
  14. Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature. 2020 02; 578(7793):102-111.
    View in: PubMed
    Score: 0.056
  15. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature. 2019 05; 569(7757):503-508.
    View in: PubMed
    Score: 0.053
  16. NetSig: network-based discovery from cancer genomes. Nat Methods. 2018 01; 15(1):61-66.
    View in: PubMed
    Score: 0.048
  17. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet. 2017 01; 49(1):10-16.
    View in: PubMed
    Score: 0.045
  18. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat Genet. 2016 08; 48(8):848-55.
    View in: PubMed
    Score: 0.043
  19. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016 06; 48(6):607-16.
    View in: PubMed
    Score: 0.043
  20. Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles. Cancer Discov. 2016 07; 6(7):714-26.
    View in: PubMed
    Score: 0.043
  21. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 Apr 26; 15(4):857-865.
    View in: PubMed
    Score: 0.043
  22. Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution. Nat Commun. 2015 Dec 07; 6:8866.
    View in: PubMed
    Score: 0.042
  23. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015 Nov; 5(11):1164-1177.
    View in: PubMed
    Score: 0.041
  24. Paired exome analysis of Barrett's esophagus and adenocarcinoma. Nat Genet. 2015 Sep; 47(9):1047-55.
    View in: PubMed
    Score: 0.041
  25. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73.
    View in: PubMed
    Score: 0.039
  26. RNF43 is frequently mutated in colorectal and endometrial cancers. Nat Genet. 2014 Dec; 46(12):1264-6.
    View in: PubMed
    Score: 0.039
  27. The genomic landscape of pediatric Ewing sarcoma. Cancer Discov. 2014 Nov; 4(11):1326-41.
    View in: PubMed
    Score: 0.038
  28. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53.
    View in: PubMed
    Score: 0.038
  29. Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
    View in: PubMed
    Score: 0.038
  30. Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
    View in: PubMed
    Score: 0.037
  31. Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. Genome Res. 2014 Jul; 24(7):1053-63.
    View in: PubMed
    Score: 0.037
  32. A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. PLoS One. 2014; 9(1):e87361.
    View in: PubMed
    Score: 0.037
  33. Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. Cancer Cell. 2014 Jan 13; 25(1):91-101.
    View in: PubMed
    Score: 0.037
  34. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nat Genet. 2014 Feb; 46(2):161-5.
    View in: PubMed
    Score: 0.037
  35. Landscape of genomic alterations in cervical carcinomas. Nature. 2014 Feb 20; 506(7488):371-5.
    View in: PubMed
    Score: 0.036
  36. Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. Nat Biotechnol. 2014 Jan; 32(1):71-5.
    View in: PubMed
    Score: 0.036
  37. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014 Jan 10; 32(2):121-8.
    View in: PubMed
    Score: 0.036
  38. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet. 2013 Dec; 45(12):1483-6.
    View in: PubMed
    Score: 0.036
  39. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013 Oct; 45(10):1134-40.
    View in: PubMed
    Score: 0.036
  40. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93.
    View in: PubMed
    Score: 0.035
  41. Punctuated evolution of prostate cancer genomes. Cell. 2013 Apr 25; 153(3):666-77.
    View in: PubMed
    Score: 0.035
  42. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013 May; 45(5):478-86.
    View in: PubMed
    Score: 0.035
  43. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013 Feb 14; 152(4):714-26.
    View in: PubMed
    Score: 0.034
  44. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013 Mar; 45(3):279-84.
    View in: PubMed
    Score: 0.034
  45. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012 Sep 14; 150(6):1107-20.
    View in: PubMed
    Score: 0.033
  46. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
    View in: PubMed
    Score: 0.033
  47. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10.
    View in: PubMed
    Score: 0.033
  48. A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
    View in: PubMed
    Score: 0.033
  49. A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. J Clin Invest. 2012 Aug; 122(8):2983-8.
    View in: PubMed
    Score: 0.033
  50. Paired-end sequencing of Fosmid libraries by Illumina. Genome Res. 2012 Nov; 22(11):2241-9.
    View in: PubMed
    Score: 0.033
  51. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 2012 Jun 20; 486(7403):405-9.
    View in: PubMed
    Score: 0.033
  52. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
    View in: PubMed
    Score: 0.033
  53. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci U S A. 2012 Mar 06; 109(10):3879-84.
    View in: PubMed
    Score: 0.032
  54. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011 Dec 29; 365(26):2497-506.
    View in: PubMed
    Score: 0.032
  55. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 04; 43(10):964-968.
    View in: PubMed
    Score: 0.031
  56. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011 Aug 26; 333(6046):1157-60.
    View in: PubMed
    Score: 0.031
  57. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
    View in: PubMed
    Score: 0.030
  58. The genomic complexity of primary human prostate cancer. Nature. 2011 Feb 10; 470(7333):214-20.
    View in: PubMed
    Score: 0.030
  59. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905.
    View in: PubMed
    Score: 0.028
  60. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010 Jan 19; 17(1):98-110.
    View in: PubMed
    Score: 0.028
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.